Paper Details

  1. Home
  2. Paper Details

Effectiveness and safety of diltiazem or lisinopril in treatment of hypertension after heart transplantation. Results of a prospective, randomized multicenter trail.

Author: BourgeR, BrozenaS C, ClemsonB, HobbsR, JohnsonM R, MillerL, MillsR M, NaftelD, OlivariM T, QuiggR, VenturaH

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Both diltiazem and lisinopril were safe for the treatment of hypertension after heart transplantation, but neither drug achieved control in a majority of patients.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: The purpose of this study was to determine the effectiveness and safety of diltiazem or lisinopril for treatment of hypertension after heart transplantation. BACKGROUND: Systemic hypertension is common after heart transplantation, and to date there are no randomized, prospective multice...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/0735-1097(96)00057-5

データ提供：米国国立医学図書館（NLM）

Managing Hypertension After Heart Transplantation: Diltiazem or Lisinopril?

Hypertension, or high blood pressure, is a common challenge after heart transplantation. Finding effective and safe medications to manage this condition is crucial for maintaining long-term health. This research compared the effectiveness and safety of two medications, diltiazem and lisinopril, in treating hypertension in patients who have undergone heart transplantation.

A Safe and Effective Approach to Post-Transplant Hypertension

The study involved 116 patients with hypertension after heart transplantation. The participants were randomly assigned to receive either diltiazem or lisinopril for at least three months. Both medications effectively lowered blood pressure, with no significant difference in the percentage of patients who responded positively to treatment. Moreover, both drugs demonstrated a favorable safety profile, with only minor and manageable side effects reported.

A Balanced Approach for Post-Transplant Care

The findings suggest that both diltiazem and lisinopril are safe and effective options for managing hypertension after heart transplantation. However, it's important to note that neither drug alone effectively controlled the condition in a majority of patients. Therefore, individualized treatment approaches, potentially involving a combination of medications or other strategies, may be necessary to achieve optimal blood pressure management in this unique population.

Dr.Camel's Conclusion

Just as a camel adapts to the changing sands of the desert, individuals who have undergone heart transplantation face a unique set of challenges. Managing hypertension is crucial for their long-term well-being. This research offers valuable insights into the effectiveness and safety of two common medications, diltiazem and lisinopril. However, remember that every patient is different, and personalized care is essential for achieving optimal health outcomes.

Date :
  1. Date Completed 1996-07-11
  2. Date Revised 2019-07-08
Further Info :

Pubmed ID

8636558

DOI: Digital Object Identifier

10.1016/0735-1097(96)00057-5

Related Literature

Article Analysis
・Side Effects of lisinopril
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.